Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 10 selected

Guidance programme

Showing 601 to 645 of 645

TitleReference numberPublishedLast updated
Padeliporfin for untreated localised prostate cancerTA546
Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaTA545
Urinary tract infection (lower): antimicrobial prescribingNG109
Prostatitis (acute): antimicrobial prescribingNG110
Pyelonephritis (acute): antimicrobial prescribingNG111
Urinary tract infection (recurrent): antimicrobial prescribingNG112
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Myeloma: diagnosis and managementNG35
Lyme diseaseNG95
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Renal replacement therapy and conservative managementNG107
Decision-making and mental capacityNG108
Cabozantinib for untreated advanced renal cell carcinomaTA542
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Chronic heart failure in adults: diagnosis and managementNG106
Preventing suicide in community and custodial settingsNG105
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Flu vaccination: increasing uptakeNG103
Dinutuximab beta for treating neuroblastomaTA538
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Community pharmacies: promoting health and wellbeingNG102
Dupilumab for treating moderate to severe atopic dermatitisTA534
Ocrelizumab for treating relapsing–remitting multiple sclerosisTA533
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Biomarker tests to help diagnose preterm labour in women with intact membranesDG33
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapyTA530
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Dementia: assessment, management and support for people living with dementia and their carersNG97
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's diseaseTA217
Guselkumab for treating moderate to severe plaque psoriasisTA521
Midostaurin for untreated acute myeloid leukaemiaTA523
Brentuximab vedotin for treating CD30-positive Hodgkin lymphomaTA524
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA525
Arsenic trioxide for treating acute promyelocytic leukaemiaTA526
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and overNG36
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan IDG32
Tocilizumab for treating giant cell arteritisTA518
Care and support of people growing older with learning disabilitiesNG96

Results per page

  1. 10
  2. 25
  3. 50
  4. All